Cargando…

Linear Regression QSAR Models for Polo-Like Kinase-1 Inhibitors

A structurally diverse dataset of 530 polo-like kinase-1 (PLK1) inhibitors is compiled from the ChEMBL database and studied by means of a conformation-independent quantitative structure-activity relationship (QSAR) approach. A large number (26,761) of molecular descriptors are explored with the main...

Descripción completa

Detalles Bibliográficos
Autor principal:	Duchowicz, Pablo R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850101/ https://www.ncbi.nlm.nih.gov/pubmed/29443884 http://dx.doi.org/10.3390/cells7020013

Ejemplares similares

QSAR analysis on tacrine-related acetylcholinesterase inhibitors
por: Wong, Kai Y, et al.
Publicado: (2014)

Network-based piecewise linear regression for QSAR modelling
por: Cardoso-Silva, Jonathan, et al.
Publicado: (2019)

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
por: Abdelfatah, Sara, et al.
Publicado: (2018)

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain
por: Chen, Yunyu, et al.
Publicado: (2016)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1)
por: Jani, Krupa S., et al.
Publicado: (2012)

The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)

The CINs of Polo-Like Kinase 1 in Cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2020)

Development of a Novel Cell-Permeable Protein–Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1
por: Huggins, David J., et al.
Publicado: (2019)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1
por: Srinivasrao, Ganipisetti, et al.
Publicado: (2014)

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
por: Abdelfatah, Sara, et al.
Publicado: (2019)

Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2019)

Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors
por: Jadhav, Mrunal, et al.
Publicado: (2021)

Polo-like kinase-1 in DNA damage response
por: Hyun, Sun-Yi, et al.
Publicado: (2014)

QSAR Study and Molecular Design of Open-Chain Enaminones as Anticonvulsant Agents
por: Garro Martinez, Juan C., et al.
Publicado: (2011)

Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases
por: Hennenberg, Martin, et al.
Publicado: (2018)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
por: Yun, Sang-Moon, et al.
Publicado: (2009)

Polo-like kinase 1 as target for cancer therapy
por: Weiß, Lily, et al.
Publicado: (2012)

Polo-like kinase 1 promotes pulmonary hypertension
por: Chen, Rongrong, et al.
Publicado: (2023)

SBE13, a newly identified inhibitor of inactive polo-like kinase 1
por: Keppner, Sarah, et al.
Publicado: (2010)

Enhanced polo-like kinase 1 expression in myelodysplastic syndromes
por: Min, Kyoung Il, et al.
Publicado: (2019)

Exploring the Binding Nature of Pyrrolidine Pocket-Dependent Interactions in the Polo-Box Domain of Polo-Like Kinase 1
por: Murugan, Ravichandran N., et al.
Publicado: (2013)

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay
por: Normandin, Karine, et al.
Publicado: (2016)

A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
por: Gatz, Susanne A., et al.
Publicado: (2019)

A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
por: Imakura, Takeshi, et al.
Publicado: (2023)

Role for polo-like kinase 4 in mediation of cytokinesis
por: Press, Michael F., et al.
Publicado: (2019)

Polo-Like Kinase 2: From Principle to Practice
por: Zhang, Chuanyong, et al.
Publicado: (2022)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
por: Dong, Jianwen, et al.
Publicado: (2018)

Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells
por: Ritter, Andreas, et al.
Publicado: (2016)

BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells
por: Chen, Er, et al.
Publicado: (2020)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe
por: Li, Jingjing, et al.
Publicado: (2015)

Histone acetyltransferase and Polo-like kinase 3 inhibitors prevent rat galactose-induced cataract
por: Kanada, Fumito, et al.
Publicado: (2019)

Polo-like kinase 1 (Plk1): an Unexpected Player in DNA Replication
por: Song, Bing, et al.
Publicado: (2012)

Polo-Like Kinase Controls Vertebrate Spindle Elongation and Cytokinesis
por: Brennan, Ian M., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_tuq7iuj2dv6dmk28j5htjkkb3q